Levin Named CFO Of Endo Pharmaceuticals
May 8, 2009 (FinancialWire) — Endo Pharmaceuticals (NASDAQ: ENDP) has named Alan G. Levin as the company’s executive vice president and chief financial officer, effective June 1. Levin was previously senior vice president and CFO of Pfizer, Inc. (NYSE: PFE), where he worked for 20 years in a range of positions.
Levin’s previous roles at Pfizer included treasurer, and SVP of finance and strategic management for the company’s research and development organization. He most recently served as EVP and CFO of Moksha8 Pharmaceuticals, a privately held, specialty pharmaceuticals company focused in Latin America and other emerging markets.
Chadds Ford, Pennsylvania-based Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty.
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.
Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
